Science and Technology
CPR builds on the proprietary antibody engineering technology developed by the Chugai Group in order to achieve our goals.
ESG at Chugai Group
Chugai Group conducts its business activities to fulfill its mission of benefiting the medical community and human health around the world.
Browse through the latest news and developments by CPR and the Chugai Group.
- Chugai in-licenses New Oral Drug Candidate for COVID-19 from Roche
- Chugai Refiles Patent Infringement Lawsuit concerning Edirol Capsules
- Chugai Obtains Approval for Use of FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic for Pemigatinib for Patients with FGFR2 Fusion Positive Biliary Tract Cancer